Tuesday, 02 January 2024 12:17 GMT

INVESTOR ALERT: Class Action Lawsuit Filed On Behalf Of Atyr Pharma, Inc. (ATYR) Investors Holzer & Holzer, LLC Encourages Investors With Significant Losses To Contact The Firm


(MENAFN- GlobeNewsWire - Nasdaq) ATLANTA, Nov. 03, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against aTyr Pharma, Inc. (“aTyr” or the“Company”) (NASDAQ: ATYR). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information concerning the efficacy of aTyr's lead therapy candidate, Efzofitimod.

If you purchased shares of aTyr between November 7, 2024 and September 12, 2025, and experienced a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at ..., by toll-free telephone at (888) 508-6832, or by visiting the firm's website at for more information.

The deadline to ask the court to be appointed lead plaintiff in the case is December 8, 2025.

Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, and 2023, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, , and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.

CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
...


MENAFN03112025004107003653ID1110288023



GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Search